Bibliografisk note

Funding Information:
We thank the patients who participated in these trials and their families, the investigators, and staff at all the TENAYA and LUCERNE clinical sites, and the members of the independent data and safety monitoring committee. We thank Aaron Osborne for his contribution to the design of the TENAYA and LUCERNE trials. F Hoffmann-La Roche (Basel, Switzerland) provided support for the study and participated in the study design; the collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the article for publication. Funding was provided by F Hoffmann-La Roche for third-party writing assistance, which was provided by Dinakar Sambandan of Envision Pharma Group. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

Funding Information:
JSH reports support from Genentech/Roche for the present manuscript; grants from Apellis, AsclepiX, Bayer, Gyroscope, Hemera, Iveric Bio, Kanghong, Kodiak, NGM, Notal Vision, Novartis, Regeneron, Regenxbio, and Stealth, outside the submitted work; and consulting fees from Apellis, AsclepiX, Bayer, Gyroscope, Hemera, Iveric Bio, Kanghong, Kodiak, NGM, Notal Vision, Novartis, Regeneron, Regenxbio, and Stealth. AMK reports grants or contracts to institution from Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug, Novartis, Ophthea, Regenxbio, and Roche, outside the submitted work; consulting fees from Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug, Novartis, Ophthea, Regenxbio, and Roche, outside the submitted work; payment or honoraria for lectures, presentations, or speaker bureaus from Allergan, Genentech, and Novartis, outside the submitted work; and has served on advisory boards for Adverum, Allergan, Chengdu Kanghong, Genentech, Novartis, Ophthea, Regenxbio, and Roche. CQR is an employee of Genentech and reports owning stocks in Roche. KB is an employee of Roche Products (Ireland). PJF reports patient care grants to institution (Vitreoretinal Consultants of New York) for various national clinical trials from Alkeus, Apellis, Chengdu Kanghong, Genentech, Gyroscope, Iveric Bio, Kodiak, NGM, and Regeneron; has served on advisory boards for Allergan and Genentech; and is the president of the American Association of Retinal Specialists (unpaid). CB is an employee of Genentech, and reports owning stocks in Roche. MSF reports consulting fees from Alcon, Bayer, Novartis, Roche, and Zeiss. HL is an employee of Genentech, and has received stock from Genentech/Roche as an employee; has received support from Genentech/Roche to attend meetings as an employee; and is a coauthor on patent application WO202123804 involving the PTI algorithm. FGH reports research grants or contracts to institution from Bayer, Bioeq/Formycon, Kanghong, Novartis, and Roche/Genentech; consulting fees from Bayer, Kanghong, Novartis, and Roche/Genentech; and payment or honoraria for lectures, presentations, or speaker bureaus from Bayer and Novartis. VP is an employee of F Hoffmann-La Roche (UK). TYYL reports grants or contracts to institution from Bayer, Chengdu Kanghong, and Novartis, outside the submitted work; consulting fees from Bayer, Boehringer Ingelheim, Novartis, Oculis, and Roche, outside the submitted work; and payment or honoraria for lectures, presentations, or speaker bureaus from Bayer, Chengdu Kanghong, Novartis, and Roche, outside the submitted work. DS is an employee of F Hoffmann-La Roche (UK); owns stock and stock options in Roche; and is a coauthor on patent application WO202123804 involving the PTI algorithm. CR reports research support from Allergan, Kodiak, Novartis, and Regeneron, outside the submitted work; and consulting fees from Allergan, Genentech, Kodiak, and Novartis, outside the submitted work. BS is an employee of F Hoffmann-La Roche. FV reports consulting fees from Bayer and Roche; payments for expert testimony from Bayer and Roche; and payments for participation on advisory boards for Bayer and Roche. CMGC reports grants or contracts from Bayer, Boehringer Ingelheim, Novartis, and Topcon, outside the submitted work; consulting fees from Novartis and Roche, outside the submitted work; speaker fees from Allergan, Bayer, Novartis, Roche, Topcon, and Zeiss, outside the submitted work; and support for travel to meetings from Bayer and Topcon. TYW reports clinical trial grants from Aldropika, Allergan, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio, Merck, Novartis, Oxurion (ThromboGenics), Roche, Samsung, Shanghai Henlius, and Zhaoke, outside the submitted work; consulting fees from Aldropika, Allergan, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio, Merck, Novartis, Oxurion (ThromboGenics), Roche, Samsung, Shanghai Henlius, and Zhaoke, outside the submitted work; payment or honoraria from Allergan, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio, Merck, Novartis, Oxurion (ThromboGenics), Roche, Samsung, Shanghai Henlius, and Zhaoke, outside the submitted work; support for travel from Aldropika, Allergan, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio, Merck, Novartis, Oxurion (ThromboGenics), Roche, Samsung, Shanghai Henlius, and Zhaoke; and has served on advisory boards of Aldropika, Allergan, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio, Merck, Novartis, Oxurion (ThromboGenics), Roche, Samsung, Shanghai Henlius, and Zhaoke.

Publisher Copyright:
© 2022 Elsevier Ltd